Track topics on Twitter Track topics that are important to you
Novo Nordisk has warned it may have to drop prices of its insulin products in the US next year, facing pressure as rival Sanofi cuts prices of its mainstay Lantus due to biosimilar competition. The Danish pharma said that it is negotiating prices ...
Original Article: Novo Nordisk may drop US insulin price as Sanofi suffersNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...